- 专利标题: Risperidone sustained release microsphere composition
-
申请号: US16144614申请日: 2018-09-27
-
公开(公告)号: US10406161B2公开(公告)日: 2019-09-10
- 发明人: Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
- 申请人: Shandong Luye Pharmaceutical Co., Ltd. , Nanjing Luye Pharmaceutical Co., Ltd.
- 申请人地址: CN Yantai CN Nanjing
- 专利权人: SHANDONG LUYE PHARMACEUTICAL CO., LTD.,NANJING LUYE PHARMACEUTICAL CO., LTD.
- 当前专利权人: SHANDONG LUYE PHARMACEUTICAL CO., LTD.,NANJING LUYE PHARMACEUTICAL CO., LTD.
- 当前专利权人地址: CN Yantai CN Nanjing
- 代理机构: Seed IP Law Group LLP
- 优先权: CN201110102840 20110425
- 主分类号: A61K9/50
- IPC分类号: A61K9/50 ; A61K31/519 ; A61K9/16 ; A61K9/19 ; A61K9/14 ; A61K47/34 ; A61K9/00 ; A61K9/48
摘要:
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
公开/授权文献
- US20190022098A1 RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION 公开/授权日:2019-01-24
信息查询